No internet connection — showing the saved version of the page.

Pharming Group NV

NLEUR
← to the screener
AS:PHARMLSE:0QCOUS:PHGUF

Pharming Group NV (AS:PHARM) — Biotechnology. Number of exchanges where the company shares trade: 3. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
pharming.com
Investor relations
pharming.com/investors
Sector
Healthcare · Biotechnology
Headquarters
Leiden, Netherlands
Management
Fabrice Chouraqui
Employees
407
Founded
1988
IPO
1998-07-02
Listed since
16.06.1999 (AS:PHARM)
Shares outstanding
707.78 M
Free float
696.57 M
Market cap
770.42 M USD
Insiders
1.91%
Institutions
22.92%
Industry (SIC)
Pharmaceutical Preparations
Legal form
B5PM
ISIN
NL0010391025
LEI
724500DCJ9MPG74JEH91
P/E
109
P/B
3.27
FCF
54.0 M USD
Debt
?
Earnings and FCF — for the 12 months to 31.12.2025 (the company's latest report).
Net income
2.85 M USD year
For the financial year to 31.12.2025
Revenue376 M USD
− Expenses350 M USD
Gross profit331 M USD
Net income2.85 M USD
History by year
RevenueExpensesLoss
31.12.2019: Revenue 189 M · Expenses 121 M · Operating profit 68.2 M · Net income 40.6 M31.12.2020: Revenue 212 M · Expenses 136 M · Operating profit 76.3 M · Net income 37.7 M31.12.2021: Revenue 199 M · Expenses 185 M · Operating profit 13.6 M · Net income 16.0 M31.12.2022: Revenue 206 M · Expenses 187 M · Operating profit 18.2 M · Net income 13.7 M31.12.2023: Revenue 245 M · Expenses 251 M · Operating profit −5.39 M · Net income −10.5 M31.12.2024: Revenue 297 M · Expenses 306 M · Operating profit −8.62 M · Net income −11.8 M31.12.2025: Revenue 376 M · Expenses 350 M · Operating profit 25.8 M · Net income 2.85 M
12.201912.2025
Green above orange is profit (revenue − expenses); red below zero is a loss.
NAV
0.39 USD · P/NAV 3.27
Balance sheet date31.12.2025
Assets500 M USD
− Liabilities223 M USD
= NAV (equity of the company's shareholders)277 M USD
= Tangible NAV277 M USD
Shares707 781 240
NAV per share0.39 USD
Tangible NAV per share0.39 USD
Share price (PHARM)1.0895 EUR
P/NAV3.27
NAV history
Balance sheet dateNAVNAV per share
31.12.2025277 M USD0.39 USD
31.12.2024221 M USD0.31 USD
Description

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
common stock
AS Euronext AmsterdamPHARM primaryEUR1.0895 +0.79%common stock
LSE London Stock Exchange0QCO IOBEUR0.8045 +0.00%common stock
US USA StocksPHGUF OTCUSD0.9545 +2.80%common stock
depositary receipt
US USA StocksPHARUSD12.13 -1.06%depositary receipt

Price

DayWeekMonth
up day down dayHover / tap a day — open, close, high and low prices

News this week

Press releases from the company's investor website, updated daily. Links lead to the company's website. Headlines are in the original language, as on the company website.

27.10.2026Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November

Top holders

HolderStakeSharesReport date
iShares Trust-iShares Co…0.89%5.81 M2026-08-31
DFA INVESTMENT TRUST CO-…0.47%3.06 M2026-07-31
iShares Trust-iShares MS…0.38%2.5 M2026-08-31
DFA INVESTMENT DIMENSION…0.28%1.85 M2026-07-31
Goldman Sachs TRT-Goldma…0.23%1.51 M2026-07-31
iShares Trust-iShares Co…0.21%1.38 M2026-08-31
iShares, Inc.-iShares MS…0.2%1.33 M2026-08-31
Dimensional ETF Trust-Di…0.17%1.13 M2026-07-31
iShares Trust-iShares Co…0.15%996 3672026-08-31
Dimensional ETF Trust-Di…0.11%706 2172026-07-31